COIOSDeep risk insights through multi-disciplinary research across the globe
a group of different colored tubes
Item refines Peer-reviewed Added

Galleri blood test found 26.7% to 37.2% of cancers per screening round

In the NHS-Galleri trial of 142,250 adults aged 50 to 77, the multi-cancer blood test detected between 26.7% and 37.2% of cancers in each of three annual screening rounds.

The NHS-Galleri trial randomised 142,250 adults aged 50 to 77 to a multi-cancer blood test added to usual care, or to usual care alone. Across three annual rounds the test detected between 26.7% and 37.2% of all cancers. The proportion of positive results that proved to be cancer fell from 58.0% in round one to 45.8% in round three.

Why it is interesting: Performance measured within a randomised population programme, in a trial that did not meet its late-stage reduction endpoint.

Source
Nature Medicine, 22 September 2026
Paper
Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial
Authors
Neal RD, Dolly S, Johnson P, Jones H, Kumar SH, Lee LYW et al.
DOI
10.1038/s41591-026-04652-8
Type
Peer-reviewed article
Design
Randomised controlled trial, 142,250 adults aged 50–77, three annual screening rounds; descriptive prespecified secondary endpoints
Verdict
Refines prior evidence
Driver
Cancer
Free full text
Free to read at the publisher
Attention
8 citations (Crossref) · as of 2026-11-18
Abstract — the authors' own words, CC BY

The NHS-Galleri trial was a randomized controlled trial evaluating a multi-cancer early detection (MCED) test added to usual care. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses in the intervention arm versus control arm was not met. Here we report prespecified secondary test performance endpoints among evaluable intervention arm participants across three annual screening rounds. These analyses were descriptive; there was no hypothesis testing. Participants aged 50-77 years (N = 142,250) were randomized 1:1 into intervention (MCED) or control arms. Intervention arm participants with positive MCED results were referred to National Health Service (NHS) standard-of-care pathways for diagnostic workup, with referrals informed by the predicted cancer signal origin (CSO). Positive test results were returned for 722 of 70,325 (1.03%), 518 of 64,498 (0.80%) and 561 of 62,323 (0.90%) participants in rounds 1-3, respectively. In aggregate, 937 participants had MCED-detected primary cancers. Respective by-round cancer detection rates were 0.60%, 0.40% and 0.41%; positive predictive values were 58.0% (419/722), 50.4% (261/518) and 45.8% (257/561); and negative predictive values were 98.98% (68,895/69,603), 98.90% (63,278/63,980) and 98.86% (61,058/61,762). Across rounds, specificity ranged from 99.50% to 99.60%; episode sensitivity ranged from 26.7% to 37.2% for all cancers and from 47.6% to 63.4% for 12 prespecified types; and CSO accuracy ranged from 91.1% to 93.6%. These data provide insights on the performance of the MCED test in population screening within the NHS setting. ClinicalTrials.gov: NCT05611632 ; ISRCTN: ISRCTN91431511 .

Other drivers in Health today